NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing

Accumulated proceeds of $3 million including the initial closing held in March 2025

ZÜRICH, June 30, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, today announced that it has completed the second and final $1 million closing of its previously disclosed $3 million equity financing of preferred shares (or equivalents) and warrants from March 2025. Pursuant to the second closing, the Company agreed to issue 606,061 preferred shares (or equivalent) at a conversion price of $1.65 per share, representing a 10% premium to the market share price on the date the original agreement was signed (March 28, 2025). The second closing occurred on June 27, 2025.

Read more at prnewswire.com